Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer immunotherapies for breast cancer and other human epidermal growth factor receptor 2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was founded in 2006 and is based in Stafford, Texas. The company trades on US exchange. The company headquarter is located in Stafford, United States.

TickerGLSI
Long NameGreenwich LifeSciences, Inc.
Short NameGreenwich LifeSciences, Inc.